Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Johnson & Johnson
  6. News
  7. Summary
    JNJ   US4781601046

JOHNSON & JOHNSON

(JNJ)
  Report
Real-time Estimate Cboe BZX  -  12:17:46 2023-02-02 pm EST
164.24 USD   -0.42%
07:10aAvalon GloboCare Partnerships, Completed Capital Raise, And Robust IP Portfolio Expose An Attractive Value Proposition ($ALBT)
AQ
12:47aFormycon Licenses Stelara Biosimilar Candidate to Fresenius Unit
MT
01/31Moody's Says Johnson & Johnson's Court Loss is Negative Credit Development
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Insider Sell: Johnson & Johnson

12/02/2022 | 04:37pm EST
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about JOHNSON & JOHNSON
07:10aAvalon GloboCare Partnerships, Completed Capital Raise, And Robust IP Portfolio Expose ..
AQ
12:47aFormycon Licenses Stelara Biosimilar Candidate to Fresenius Unit
MT
01/31Moody's Says Johnson & Johnson's Court Loss is Negative Credit Development
MT
01/31Federal Appellate Court Rejects Controversial J&J Ploy to Dodge Talc Cancer Lawsuits
PR
01/31With Multiple Shots On Revenue-Generating Goals, Avalon GloboCare Positions For A Break..
AQ
01/31Solid results for Pets at home and UBS: MarketScree..
MS
01/31Idorsia Files European Marketing Authorization Application For Resistant Hypertension T..
MT
01/30Federal Appellate Court Rejects Controversial J&J Ploy to Dodge Talc Cancer Lawsuits
PR
01/30Sector Update: Health Care Stocks' Losses Gain Speed Near Monday Close
MT
01/30Sector Update: Health Care
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 017 M - -
Net income 2022 20 668 M - -
Net cash 2022 10 806 M - -
P/E ratio 2022 20,8x
Yield 2022 2,67%
Capitalization 431 B 431 B -
EV / Sales 2022 4,42x
EV / Sales 2023 4,19x
Nbr of Employees 141 700
Free-Float 83,8%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 164,92 $
Average target price 180,90 $
Spread / Average Target 9,69%
EPS Revisions
Managers and Directors
Joaquin Duato Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
James D. Swanson Global Chief Information Officer & Executive VP
Dan Zelem Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-6.64%431 181
ELI LILLY AND COMPANY-5.93%325 502
NOVO NORDISK A/S0.47%312 239
MERCK & CO., INC.-3.58%271 237
ROCHE HOLDING AG-3.82%269 501
ABBVIE INC.-9.29%259 171